Logo image of ALBPS.PA

BIOPHYTIS (ALBPS.PA) Stock Fundamental Analysis

Europe - Euronext Paris - EPA:ALBPS - FR001400OLP5 - Common Stock

0.0611 EUR
+0 (+0.49%)
Last: 1/8/2026, 7:00:00 PM
Fundamental Rating

0

ALBPS gets a fundamental rating of 0 out of 10. The analysis compared the fundamentals against 83 industry peers in the Biotechnology industry. ALBPS has a bad profitability rating. Also its financial health evaluation is rather negative. ALBPS has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year ALBPS has reported negative net income.
In the past year ALBPS has reported a negative cash flow from operations.
In the past 5 years ALBPS always reported negative net income.
In the past 5 years ALBPS always reported negative operating cash flow.
ALBPS.PA Yearly Net Income VS EBIT VS OCF VS FCFALBPS.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

ALBPS has a Return On Assets of -121.29%. This is amonst the worse of the industry: ALBPS underperforms 80.72% of its industry peers.
Industry RankSector Rank
ROA -121.29%
ROE N/A
ROIC N/A
ROA(3y)-132.24%
ROA(5y)-115.97%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ALBPS.PA Yearly ROA, ROE, ROICALBPS.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 0 0 0 0 0 0 0 0 0 0

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ALBPS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ALBPS.PA Yearly Profit, Operating, Gross MarginsALBPS.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

0

2. Health

2.1 Basic Checks

ALBPS has more shares outstanding than it did 1 year ago.
The number of shares outstanding for ALBPS has been reduced compared to 5 years ago.
ALBPS has a worse debt/assets ratio than last year.
ALBPS.PA Yearly Shares OutstandingALBPS.PA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
ALBPS.PA Yearly Total Debt VS Total AssetsALBPS.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

ALBPS has an Altman-Z score of -11.48. This is a bad value and indicates that ALBPS is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of ALBPS (-11.48) is worse than 77.11% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -11.48
ROIC/WACCN/A
WACCN/A
ALBPS.PA Yearly LT Debt VS Equity VS FCFALBPS.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M -20M

2.3 Liquidity

A Current Ratio of 0.35 indicates that ALBPS may have some problems paying its short term obligations.
ALBPS has a Current ratio of 0.35. This is amonst the worse of the industry: ALBPS underperforms 89.16% of its industry peers.
A Quick Ratio of 0.35 indicates that ALBPS may have some problems paying its short term obligations.
ALBPS's Quick ratio of 0.35 is on the low side compared to the rest of the industry. ALBPS is outperformed by 87.95% of its industry peers.
Industry RankSector Rank
Current Ratio 0.35
Quick Ratio 0.35
ALBPS.PA Yearly Current Assets VS Current LiabilitesALBPS.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 87.16% over the past year.
EPS 1Y (TTM)87.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%89.17%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 14.19% on average over the next years. This is quite good.
The Revenue is expected to decrease by -46.55% on average over the next years. This is quite bad
EPS Next Y48.09%
EPS Next 2Y14.19%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-78.57%
Revenue Next 2Y-46.55%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

ALBPS.PA Yearly Revenue VS EstimatesALBPS.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2024 2025 2026 10M 20M 30M 40M
ALBPS.PA Yearly EPS VS EstimatesALBPS.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 -100 -200 -300 -400

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ALBPS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ALBPS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALBPS.PA Price Earnings VS Forward Price EarningsALBPS.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALBPS.PA Per share dataALBPS.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -0.5 -1

4.3 Compensation for Growth

ALBPS's earnings are expected to grow with 14.19% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y14.19%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

ALBPS does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

BIOPHYTIS

EPA:ALBPS (1/8/2026, 7:00:00 PM)

0.0611

+0 (+0.49%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-13 2025-08-13
Earnings (Next)N/A N/A
Inst Owners3.07%
Inst Owner ChangeN/A
Ins Owners0.42%
Ins Owner ChangeN/A
Market Cap700.22K
Revenue(TTM)N/A
Net Income(TTM)-8.03M
Analysts84.44
Price Target0.79 (1192.96%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)2.25%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.84
EYN/A
EPS(NY)-1.5
Fwd EYN/A
FCF(TTM)-1.47
FCFYN/A
OCF(TTM)-1.46
OCFYN/A
SpS0
BVpS-0.68
TBVpS-0.91
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -121.29%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-132.24%
ROA(5y)-115.97%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.35
Quick Ratio 0.35
Altman-Z -11.48
F-Score2
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)28.6%
Cap/Depr(5y)54.57%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)87.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%89.17%
EPS Next Y48.09%
EPS Next 2Y14.19%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-78.57%
Revenue Next 2Y-46.55%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y33.06%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-22.22%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y1.33%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y0.87%
OCF growth 3YN/A
OCF growth 5YN/A

BIOPHYTIS / ALBPS.PA FAQ

What is the fundamental rating for ALBPS stock?

ChartMill assigns a fundamental rating of 0 / 10 to ALBPS.PA.


What is the valuation status for ALBPS stock?

ChartMill assigns a valuation rating of 0 / 10 to BIOPHYTIS (ALBPS.PA). This can be considered as Overvalued.


Can you provide the profitability details for BIOPHYTIS?

BIOPHYTIS (ALBPS.PA) has a profitability rating of 0 / 10.


Can you provide the financial health for ALBPS stock?

The financial health rating of BIOPHYTIS (ALBPS.PA) is 0 / 10.